Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study

SUMMARY BACKGROUND: Myelofibrosis is a chronic myeloproliferative neoplasm characterised by splenomegaly, cytopenias, bone marrow fibrosis, and debilitating symptoms including fatigue, weight loss, and bone pain. Mutations in Janus kinase-2 (JAK2) occur in approximately 50% of patients. The only app...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Haematol
Main Authors: Harrison, Claire N, Schaap, Nicolaas, Vannucchi, Alessandro M, Kiladjian, Jean-Jacques, Tiu, Ramon V, Zachee, Pierre, Jourdan, Eric, Winton, Elliott, Silver, Richard T, Schouten, Harry C, Passamonti, Francesco, Zweegman, Sonja, Talpaz, Moshe, Lager, Joanne, Shun, Zhenming, Mesa, Ruben A
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8207822/
https://ncbi.nlm.nih.gov/pubmed/28602585
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3026(17)30088-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados